Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Onkologie. 2008 Apr;31(4):174-8. doi: 10.1159/000116736. Epub 2008 Mar 20.

EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients.

Author information

  • 1Guangdong Provincial People's Hospital, Cancer Center, Guangdong Provincial Lung Cancer Research Institute, Guangzhou, China.

Abstract

BACKGROUND:

For gefitinib treatment for non-small cell lung cancer (NSCLC), KRAS mutations reportedly behave as a resistance marker, and the epidermal growth factor receptor (EGFR) as a responsive marker. It is known that Asians and Caucasians have different responses to gefitinib. We investigated the KRAS and EGFR mutation status in a group of Chinese patients with advanced NSCLC who were treated with gefitinib after a failed chemotherapy.

MATERIAL AND METHODS:

Genomic DNA extracted from tumor specimens of 24 patients with advanced NSCLC, who failed at least 1 prior platinum-based chemotherapy regimen before gefitinib treatment, was subjected to nested polymerase chain reaction (PCR) to amplify codons 12, 13, 59, and 61 of the KRAS gene and exons 18-21 of the EGFR gene for direct sequencing.

RESULTS:

For the 24 patients, no KRAS gene mutation was found. 15 patients (62.5%, 15/24) harbored EGFR mutations which included deletion mutations in exon 19 and missense mutations in exon 21.

CONCLUSION:

KRAS mutation may occur at a very low frequency in Chinese NSCLC patients regardless of pathology, smoking status, or gender. Unlike EGFR, the low incidence of KRAS mutations may undermine its role in predicting the clinical response to EGFR tyrosine kinase inhibitors.

2008 S. Karger AG, Basel.

PMID:
18418018
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for S. Karger AG, Basel, Switzerland
    Loading ...
    Write to the Help Desk